JAK Family Expression And Therapeutic Implications In Primary Cicatricial Alopecias

The study by Lasheras-Pérez et al. investigates the expression of JAK proteins in primary cicatricial alopecias (PCA) and suggests the JAK/TYK/STAT pathway as a potential therapeutic target. The research highlights the presence of JAK3 and TYK2 in lesional infiltrates of PCA subtypes like lichen planopilaris (LPP), frontal fibrosing alopecia (FFA), and folliculitis decalvans (FD), with TYK2 showing strong expression in FD. A retrospective cohort of 19 LPP patients treated with oral JAK inhibitors showed clinical improvement, supporting the pathway's therapeutic potential. However, challenges remain, such as understanding disease heterogeneity, stem-cell dynamics, and treatment responses. The study calls for further rigorous trials to validate JAK inhibition as a viable treatment strategy for PCA.